Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
On July 9, 2026, Ionis Pharmaceuticals (NASDAQ: IONS) experienced a steep sell-off after two of its experimental therapies missed key clinical endpoints. Eplontersen failed in Phase 3 trials for transthyretin amyloid cardiomyopathy and tominersen also underperformed in Huntington's disease studies. These setbacks led to more than a 20% drop on that day, with the stock still down about 30% from its July peak despite some recent recovery. However, analysts argue this sell-off was overdone due to Ionis' strong fundamentals and successful proprietary therapies. The company's fully owned drugs like Dawnzera saw sequential sales growth of 63%, while Tryngolza received FDA approval for a new indication in June with projected peak annual sales exceeding $3 billion. Additionally, the FDA is expected to make an announcement on zilganersen by September 22. Despite its high forward earnings multiple near 91, many analysts believe Ionis remains attractively valued due to strong long-term growth potential and a consensus price target significantly higher than current levels.
Topics: biotech clinical trials pharmaceuticals stock decline